Healthy Living

The Potential for Pediatric Multiple Sclerosis Treatment

Fingolimod shows potential for pediatric MS

Recent findings of a study show that the drug fingolimod can be effective for children under the age of 18. Professor Orla Hardiman, a consultant neurologist at Beaumont Hospital and Director of Trinity Biomedical Sciences Institute recently presented these findings to international doctors at the European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS). Fingolimod is not new for MS treatment, but it is for children. Previously it has only been used for adult patients who have relapsing-remitting MS. Hardiman explains that one of the difficulties with treating children with MS is that they often have more frequent relapses, and may acquire physical disabilities earlier on.